Chris Ehrlich has been promoted to venture partner at venture capital firm InterWest Partners. He will continue to identify and evaluate new investment opportunities in the life sciences sector.
Prior to joining InterWest, Ehrlich was director of business development at Purdue Pharma, a specialty pharmaceutical company located in Stamford, Conn. Before that, he worked in business development at Genentech. He holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a BA from Dartmouth College.
Amit Kumar and Rigdon Currie have joined the board of directors of Acacia Research of Newport Beach, Calif., which consists of Acacia Technologies and CombiMatrix.
Kumar has been CEO and president of CombiMatrix since September 2001 and a director since September 2000. Prior to that, he was president and CEO of Signature BioSciences, a life science company developing technology for research in genomics, proteomics, and drug discovery. Before that, he was an entrepreneur in residence with venture capital firm Oak Investment Partners. Kumar holds a bachelor’s degree in chemistry from Occidental College and a PhD from Caltech.
Currie has been a director of CombiMatrix since March 1997. Since 1999, he has been an independent venture capital consultant. Prior to that, he was a partner of MK Global Ventures. He is also a director of Disc, a computer software company. Currie holds a BSIE from the Georgia Institute of Technology and an MBA from Harvard Business School.
Acacia’s CombiMatrix group is developing biochips.
Joseph Reiser has been appointed president and CEO of Blue Bell, Pa.-based Locus Discovery. Most recently, Reiser was president and CEO of Cytogen and will remain a member of that company’s board of directors. Prior to that, he held various positions in research and development, business development, and marketing and sales at Berlex Laboratories, the US subsidiary of Schering.
Locus identifies binding sites on protein disease targets computationally and generates small molecules that bind specifically to those protein sites. It is currently testing drug candidates for the treatment of HIV/AIDS, cancer, stroke, arthritis, and inflammation.